Calliditas presenterar data vid ERA-kongressen i Stockholm

Calliditas tillkännagav idag kommande datapresentationer och ett sponsrat symposium vid den 61:a European Renal Association (ERA) kongress, som hålls i Stockholm, Sverige den 23 – 26 maj 2024 .

Data presentations will include an efficacy analysis of Nefecon (TARPEYO® (budesonide) delayed release capsules)) in primary immunoglobulin A nephropathy (IgAN) as well as a real-world analysis of the challenges associated with the use of systemic glucocorticoids (SGC) in IgAN. “We are delighted to participate in ERA and look forward to engaging with the leaders in the renal space,” said Richard Philipson, Chief Medical Officer at Calliditas.

“We are especially excited to be in Stockholm, where Calliditas is headquartered and where we developed the first treatment specifically designed for IgA nephropathy, to present analyses that highlight the continued opportunity for our treatment to address the significant unmet need in this rare disease.” The presentation and symposium details are below. Following the meeting, they will be available on the Presentations and Publications page on Calliditas’ corporate website.

Presentation Details:
Title: “Matching-adjusted indirect comparison of eGFR in patients with immunoglobulin A nephropathy treated with Nefecon (TRF budesonide) or sparsentan”
Oral Poster Presentation: 501129
Date and Time: May 25 3:15-4:30 CET
Location: Focused Oral Room 3
Title: “Real-world challenges associated with the use of systemic glucocorticoids in a US IgAN cohort”
Poster Number: 2533
Date and Time: May 26 8:54-9:06 CET Location: A5